<産業資料/調査レポートの題名> 2022年7月19日

感染症治療薬の世界市場2019-2023


◆英文タイトル:Global Infectious Disease Therapeutics Market 2019-2023

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Antiviral – Market size and forecast 2018-2023
• Antibacterial – Market size and forecast 2018-2023
• Antifungal – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• F. Hoffmann-La Roche
• Gilead
• Merck
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Phase III pipeline drugs for infectious diseases
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Antiviral – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antiviral – Year-over-year growth 2019-2023 (%)
Exhibit 23: Antibacterial – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antibacterial – Year-over-year growth 2019-2023 (%)
Exhibit 25: Antifungal – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antifungal – Year-over-year growth 2019-2023 (%)
Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others – Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Pipeline drugs for infectious diseases
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie – Vendor overview
Exhibit 50: AbbVie – Business segments
Exhibit 51: AbbVie – Organizational developments
Exhibit 52: AbbVie – Geographic focus
Exhibit 53: AbbVie – Key offerings
Exhibit 54: F. Hoffmann-La Roche – Vendor overview
Exhibit 55: F. Hoffmann-La Roche – Business segments
Exhibit 56: F. Hoffmann-La Roche – Organizational developments
Exhibit 57: F. Hoffmann-La Roche – Geographic focus
Exhibit 58: F. Hoffmann-La Roche – Segment focus
Exhibit 59: F. Hoffmann-La Roche – Key offerings
Exhibit 60: Gilead – Vendor overview
Exhibit 61: Gilead – Business segments
Exhibit 62: Gilead – Organizational developments
Exhibit 63: Gilead – Geographic focus
Exhibit 64: Gilead – Segment focus
Exhibit 65: Gilead – Key offerings
Exhibit 66: Merck – Vendor overview
Exhibit 67: Merck – Business segments
Exhibit 68: Merck – Organizational developments
Exhibit 69: Merck – Geographic focus
Exhibit 70: Merck – Segment focus
Exhibit 71: Merck – Key offerings
Exhibit 72: Sanofi – Vendor overview
Exhibit 73: Sanofi – Business segments
Exhibit 74: Sanofi – Organizational developments
Exhibit 75: Sanofi – Geographic focus
Exhibit 76: Sanofi – Segment focus
Exhibit 77: Sanofi – Key offerings
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark